Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.
A decision is due on Bristol’s new leukaemia project, while Mallinckrodt and Mesoblast await their fates after mixed panel meetings.
Astrazeneca’s Lynparza is due US approval decisions in prostate and ovarian cancers, while Bristol's Opdivo’s fate will be determined in lung cancer.
Genmab is seeking data to position tisotumab as its first in-house launch, while Zogenix wants Fintepla to challenge GW in Lennox-Gastaut syndrome.
Smaller projects dominate the list, but this doesn’t make them any less important for November’s hopefuls.
December will be a big month for Achillion's complement inhibitor and Aquestive's ALS hopes.